You are viewing the site in preview mode
Skip to main content
|
No
|
Delay (h)
|
PT (sec)
|
Biophen® DiXaI (ng/ml)
|
Estimated cc at trough (ng/ml)
|
Clearance (L/h)
|
Potential PK drug interactions
|
Potential PD drug interactions
|
|---|
|
1
|
28
|
18.7
|
84.8
|
98
|
3.3
|
–
|
Ibuprofen
|
|
2
|
22
|
19.6
|
237.5
|
181
a
|
2.0
|
Diltiazem (↑), Clarithromycin (↑)
|
Escitalopram
|
|
3
|
38
|
15.4
|
70.8
|
125
a
|
2.9
|
Simvastatin (↑)
|
/
|
|
4
|
27
|
17.7
|
58.3
|
69
|
3.9
|
–
|
Diclofenac, Escitalopram
|
|
5
|
27
|
N/K
|
139.4
|
134
a
|
2.4
|
Amiodarone (↑)
|
Aspirin
|
|
6
|
26
|
12.9
|
4.9
|
12
|
7.9
|
Amiodarone (↑)
|
/
|
|
7
|
37
|
14.4
|
18.3
|
44
|
4.8
|
Diltiazem (↑)
|
/
|
|
8
|
27
|
15.3
|
86.5
|
89
|
3.0
|
/
|
/
|
|
9
|
9
|
26.0
|
357.8
|
251
a
|
3.2
|
/
|
/
|
|
10
|
13
|
N/K
|
184.7
|
72
|
3.9
|
/
|
Duloxetine, Paroxetine
|
- Biophen®DiXaI Biophen® Direct Factor Xa Inhibitors, cc concentration, N/K not known, PD pharmacodynamics, PK pharmacokinetics, PT prothrombin time (normal range: 12.4–14.5 s), ↑: increased plasma concentrations, ↓: decreased plasma concentrations
- aEstimated trough concentration above the on-therapy range (we considered higher-than-expected rivaroxaban levels for patient 5, as measured concentration was higher than 136 ng/ml)
